Evidence map›Paper›PMID 30371180›Full record

ArticleJournal of the American Heart Association2018

Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction: MESA.

Mohamed Faher Almahmoud, Elsayed Z Soliman, Alain G Bertoni, Bryan Kestenbaum, Ronit Katz, João A C Lima, Pamela Ouyang, P Elliott Miller, Erin D Michos, David M Herrington

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Mohamed Faher Almahmoud1 Department of Internal Medicine Section on Cardiology Wake Forest School of Medicine Winston-Salem NC.
Elsayed Z Soliman1 Department of Internal Medicine Section on Cardiology Wake Forest School of Medicine Winston-Salem NC.
Alain G Bertoni2 Department of Epidemiology and Prevention Wake Forest School of Medicine Winston-Salem NC.
Bryan Kestenbaum3 Division of Nephrology Department of Medicine Kidney Research Institute University of Washington Seattle WA.
Ronit Katz3 Division of Nephrology Department of Medicine Kidney Research Institute University of Washington Seattle WA.
João A C Lima4 Department of Radiology Johns Hopkins University School of Medicine Baltimore MD.
Pamela Ouyang5 Division of Cardiology Johns Hopkins University School of Medicine Baltimore MD.
P Elliott Miller6 Department of Critical Care Medicine National Institutes of Health Bethesda MD.
Erin D Michos5 Division of Cardiology Johns Hopkins University School of Medicine Baltimore MD.
David M Herrington1 Department of Internal Medicine Section on Cardiology Wake Forest School of Medicine Winston-Salem NC.
Wake Forest University · USJohns Hopkins University · USJohns Hopkins Medicine · USKidney Research UK · GBNational Institutes of Health Clinical Center · USNorthwest Kidney Centers · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Transition from Risk Factors to Early HF: Prevalence, Pathogenesis, and PhenomicsR01HL127028 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BERTONI, ALAIN GERALD, SHAH, SANJIV J · 2015 to 2018
$6.5M
NHLBI NIH HHS HHSN268201500003CNHLBI NIH HHS HHSN268201500003INHLBI NIH HHS R01 HL127028
6 · The paper itself

Abstract

Background Higher fibroblast growth factor-23 ( FGF -23) levels are associated with incident heart failure ( HF ) in MESA (the Multiethnic Study of Atherosclerosis). FGF -23 is also associated with left ventricular hypertrophy. Whether the FGF -23 association with HF is similar for heart failure with reduced ejection fraction ( HF r EF ) and heart failure with preserved ejection fraction ( HF p EF ) is not well established. Methods and Results We studied 6542 participants (mean age 62±10 years, 53% women, mean estimated glomerular filtration rate of 81±18 mL/min per 73 m

Indexed as

AgedAged, 80 and overBiomarkersFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsFollow-Up StudiesHeart FailureHumansMagnetic Resonance Imaging, CineMaleMiddle AgedPrognosisProspective StudiesSeverity of Illness IndexStroke VolumeBiomarkersFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth Factorsejection fractionfibroblast growth factorheart failureleft ventricular hypertrophy

Identifiers

PMID30371180
PMCPMC6222949
OpenAlexW2891220211

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.